"With today's
rebate-dominated drug formulary development model, although the class may get
crowded with 'me too' drugs, we are not encouraged that unit cost as determined
by cost per treatment for 30 days will come down."
— Mesfin
Tegenu, R.Ph., president of PerformRx, spoke with AIS's RADAR on Drug Benefits
about the FDA's recent approval of Biogen Inc. and Alkermes' Vumerity for the
treatment of multiple sclerosis, and the evolution of the oral
disease-modifying therapy (DMT) class.
No comments:
Post a Comment